China is going to be a huge market for the TAVR product. People there are living longer and require high qualifty and longer lasting valves for the operations. Venus Medtech, a Hong Kong based TAVR maker, rasied US$300 millions via IPO in december last year to be the first local Chinese TAVR maker to support growth in the region.
Early this month, Edwards Lifesciences said it received regulatory approval in China for its Sapien 3 transcatheter heart valve as an alternative treatment for patients with severe aortic stenosis who are at high risk for open heart surgery.
Anteris's ADAPT tissue and TAVR products shall be on everyone's radar!!!
DYOR!
New AVR detailed research report with valuations, page-24
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.80 |
Change
0.020(0.20%) |
Mkt cap ! $207.1M | |||
| Open | High | Low | Value | Volume |
| $9.85 | $10.78 | $9.60 | $572.9K | 57.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5627 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 931 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |